We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Inadequate Investigations Into Drug Defects Prompt 483 for Millennium
Inadequate Investigations Into Drug Defects Prompt 483 for Millennium
June 4, 2012
Quality control personnel at Millennium Pharmaceuticals’ Cambridge, Mass., facility failed to adequately investigate particles found in several lots of contract-manufactured Velcade, an injectable oncology drug, an FDA Form 483 states.